The context of prostate cancer genomics in personalized medicine (Review)
- Authors:
- Yanling Liu
-
Affiliations: Department of Oncology‑Pathology, Karolinska Institutet, Stockholm SE‑171 76, Sweden - Published online on: March 24, 2017 https://doi.org/10.3892/ol.2017.5911
- Pages: 3347-3353
This article is mentioned in:
Abstract
Lowrance WT and Scardino PT: Predictive models for newly diagnosed prostate cancer patients. Rev Urol. 11:117–126. 2009.PubMed/NCBI | |
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P and Etzioni R: Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 65:1046–1055. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhou Y, Bolton EC and Jones JO: Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol. 54:R15–R29. 2015. View Article : Google Scholar : PubMed/NCBI | |
Brooke GN, Parker MG and Bevan CL: Mechanisms of androgen receptor activation in advanced prostate cancer: Differential co-activator recruitment and gene expression. Oncogene. 27:2941–2950. 2008. View Article : Google Scholar : PubMed/NCBI | |
Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z and Baniahmad A: Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget. 6:35542–35555. 2015.PubMed/NCBI | |
Grant CM and Kyprianou N: Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Transl Androl Urol. 2:202–211. 2013.PubMed/NCBI | |
Khan MI, Hamid A, Adhami VM, Lall RK and Mukhtar H: Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des. 21:1240–1248. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS and Yao SL: Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. Eur Urol. 68:805–811. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E and Yao SL: Outcomes of localized prostate cancer following conservative management. JAMA. 302:1202–1209. 2009. View Article : Google Scholar : PubMed/NCBI | |
Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L and Lukka H: Genitourinary Radiation Oncologists of Canada: Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J. 6:121–127. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ma Q and Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 63:437–459. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brücher B, Stojadinovic A and Man YG: Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer. 5:3–24. 2014. View Article : Google Scholar : PubMed/NCBI | |
Aftimos PG, Barthelemy P and Awada A: Molecular biology in medical oncology: Diagnosis, prognosis, and precision medicine. Discov Med. 17:81–91. 2014.PubMed/NCBI | |
Schrecengost R and Knudsen KE: Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 40:244–258. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ and Brown M: A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 27:380–392. 2007. View Article : Google Scholar : PubMed/NCBI | |
Shaikhibrahim Z and Wernert N: ETS transcription factors and prostate cancer: The role of the family prototype ETS-1 (Review). Int J Oncol. 40:1748–1754. 2012.PubMed/NCBI | |
Cancer Genome Atlas Research Network: The molecular taxonomy of primary prostate cancer. Cell. 163:1011–1025. 2015. View Article : Google Scholar : PubMed/NCBI | |
Integrative Onco Genomics: Prostate adenocarcinoma. https://www.intogen.org/search?cancer=PRAD#driversAccessed. September 5–2016. | |
Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, et al: SPOP mutation leads to genomic instability in prostate cancer. Elife. 4:pii: e09207. 2015. View Article : Google Scholar : PubMed/NCBI | |
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI | |
Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, et al: Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 63:920–926. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, et al: Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci USA. 111:11139–11144. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ and Donkena KV: Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res. 18:2882–2895. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM and Nelson WG: Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol. 46:698–708. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rönnau CG, Verhaegh GW, Luna-Velez MV and Schalken JA: Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int. 2014:5917032014. View Article : Google Scholar : PubMed/NCBI | |
Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, et al: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 29:742–749. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A and Perera RJ: Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 19:14–20. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, Neves AF, Nasciutti LE, Goulart LR and Gimba ER: PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 12:5072012. View Article : Google Scholar : PubMed/NCBI | |
Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI | |
Crawford ED, Ventii K and Shore ND: New biomarkers in prostate cancer. Oncology (Williston Park). 28:135–142. 2014.PubMed/NCBI | |
Schoenborn JR, Nelson P and Fang M: Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 19:4058–4066. 2013. View Article : Google Scholar : PubMed/NCBI | |
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324:1156–1161. 1991. View Article : Google Scholar : PubMed/NCBI | |
Cui Y, Cao W, Li Q, Shen H, Liu C, Deng J, Xu J and Shao Q: Evaluation of prostate cancer antigen 3 for detecting prostate cancer: A systematic review and meta-analysis. Sci Rep. 6:257762016. View Article : Google Scholar : PubMed/NCBI | |
Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, et al: The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 16:900–908. 2014. View Article : Google Scholar : PubMed/NCBI | |
Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, et al: PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 74:1651–1660. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jiang N, Zhu S, Chen J, Niu Y and Zhou L: A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: A meta-analysis of 4,385 participants. PLoS One. 8:e743862013. View Article : Google Scholar : PubMed/NCBI | |
Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 22:2790–2799. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, et al: Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev. 14:1424–1432. 2005. View Article : Google Scholar : PubMed/NCBI | |
Feng FY, Brenner JC, Hussain M and Chinnaiyan AM: Molecular pathways: Targeting ETS gene fusions in cancer. Clin Cancer Res. 20:4442–4448. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hägglöf C, Hammarsten P, Strömvall K, Egevad L, Josefsson A, Stattin P, Granfors T and Bergh A: TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One. 9:e868242014. View Article : Google Scholar : PubMed/NCBI | |
Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, et al: Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 102:678–684. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, et al: A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst. 108:pii: djv346. 2015. View Article : Google Scholar : PubMed/NCBI | |
Shivapurkar N and Gazdar AF: DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med. 10:123–132. 2010. View Article : Google Scholar : PubMed/NCBI | |
Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R and Schulz WA: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 91:985–994. 2004.PubMed/NCBI | |
Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA and Chinnaiyan AM: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68:645–649. 2008. View Article : Google Scholar : PubMed/NCBI | |
Martin NE: New developments in prostate cancer biomarkers. Curr Opin Oncol. 28:248–252. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, et al: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 12:245–255. 2011. View Article : Google Scholar : PubMed/NCBI | |
Alshalalfa M, Crisan A, Vergara IA, Ghadessi M, Buerki C, Erho N, Yousefi K, Sierocinski T, Haddad Z, Black PC, et al: Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int. 116:556–567. 2015. View Article : Google Scholar : PubMed/NCBI | |
Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, et al: An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis. 17:81–90. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chun FK, Müller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, Graefen M, Pantel K, Huland H and Schwarzenbach H: Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 98:544–548. 2006. View Article : Google Scholar : PubMed/NCBI | |
Danila DC, Fleisher M and Scher HI: Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 17:3903–3912. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rapisuwon S, Vietsch EE and Wellstein A: Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. 14:211–222. 2016. View Article : Google Scholar : PubMed/NCBI | |
Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, et al: Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 70:740–748. 2016. View Article : Google Scholar : PubMed/NCBI | |
Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, et al: Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 21:3061–3070. 2015. View Article : Google Scholar : PubMed/NCBI | |
Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, et al: Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PLoS One. 11:e01559012016. View Article : Google Scholar : PubMed/NCBI | |
Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, et al: Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 70:45–53. 2016. View Article : Google Scholar : PubMed/NCBI | |
McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, et al: A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2:882–889. 2016. View Article : Google Scholar : PubMed/NCBI | |
Crawford ED, Higano CS, Shore ND, Hussain M and Petrylak DP: Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies. J Urol. 194:1537–1547. 2015. View Article : Google Scholar : PubMed/NCBI | |
Mitsiades N: A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res. 73:4599–4605. 2013. View Article : Google Scholar : PubMed/NCBI | |
Khemlina G, Ikeda S and Kurzrock R: Molecular landscape of prostate cancer: Implications for current clinical trials. Cancer Treat Rev. 41:761–766. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL and Saad F: Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 26:2044–2056. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kahn B, Collazo J and Kyprianou N: Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci. 10:588–595. 2014. View Article : Google Scholar : PubMed/NCBI | |
Antonarakis ES and Armstrong AJ: Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 14:192–205. 2011. View Article : Google Scholar : PubMed/NCBI | |
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kachroo N, Warren AY and Gnanapragasam VJ: Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men. BMC Cancer. 14:6732014. View Article : Google Scholar : PubMed/NCBI | |
Jørgensen JT: Drug-diagnostics co-development in oncology. Front Oncol. 4:2082014.PubMed/NCBI | |
Olsen D and Jørgensen JT: Companion diagnostics for targeted cancer drugs-clinical and regulatory aspects. Front Oncol. 4:1052014. View Article : Google Scholar : PubMed/NCBI | |
Rueff J and Rodrigues AS: Cancer drug resistance: A brief overview from a genetic viewpoint. Methods Mol Biol. 1395:1–18. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li MM, Monzon FA, Biegel JA, Jobanputra V, Laffin JJ, Levy B, Leon A, Miron P, Rossi MR, Toruner G, et al: A multicenter, cross-platform clinical validation study of cancer cytogenomic arrays. Cancer Genet. 208:525–536. 2015. View Article : Google Scholar : PubMed/NCBI | |
Trevino V, Falciani F and Barrera-Saldaña HA: DNA microarrays: A powerful genomic tool for biomedical and clinical research. Mol Med. 13:527–541. 2007. View Article : Google Scholar : PubMed/NCBI | |
Myllykangas S and Ji HP: Targeted deep resequencing of the human cancer genome using next-generation technologies. Biotechnol Genet Eng Rev. 27:135–158. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kinde I, Wu J, Papadopoulos N, Kinzler KW and Vogelstein B: Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 108:9530–9535. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA, Mattick JS and Rinn JL: Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol. 30:99–104. 2012. View Article : Google Scholar | |
Scolnick JA, Dimon M, Wang IC, Huelga SC and Amorese DA: An efficient method for identifying gene fusions by targeted RNA sequencing from fresh frozen and FFPE samples. PLoS One. 10:e01289162015. View Article : Google Scholar : PubMed/NCBI | |
Weirather JL, Afshar PT, Clark TA, Tseng E, Powers LS, Underwood JG, Zabner J, Korlach J, Wong WH and Au KF: Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing. Nucleic Acids Res. 43:e1162015. View Article : Google Scholar : PubMed/NCBI | |
Zheng GX, Lau BT, Schnall-Levin M, Jarosz M, Bell JM, Hindson CM, Kyriazopoulou-Panagiotopoulou S, Masquelier DA, Merrill L, Terry JM, et al: Haplotyping germline and cancer genomes with high-throughput linked-read sequencing. Nat Biotechnol. 34:303–311. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gawad C, Koh W and Quake SR: Single-cell genome sequencing: Current state of the science. Nat Rev Genet. 17:175–188. 2016. View Article : Google Scholar : PubMed/NCBI | |
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar : PubMed/NCBI |